National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from severe H5N1 avian influenza.
National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from severe H5N1 avian influenza.
Read More
Preclinical data reveals CAN10’s potential to target key proteins involved in systemic sclerosis-associated interstitial lung disease and idiopathic pulmonary fibrosis.
Read More
The saliva test provides a more accurate and child-friendly alternative to blood tests for predicting the severity of respiratory infections, research finds.
Read More
The investigational therapy, targeting the B7-H3 antigen, has shown promising tumor-killing effects and a good safety profile in preclinical models.
Read More
The discovery shows that the “dark side” of influenza virus protein has unique, previously untapped epitopes that could be applied to the development of new vaccine and treatment strategies.
Read More
Lactating mothers who get the COVID-19 booster pass along the antibodies to their children via their breast milk and potentially protect babies too young to receive the vaccine.
Read More
Researchers say the study results challenge the idea that mRNA-based vaccine immunity wanes quickly.
Read More
The US CDC has issued advice for healthcare providers to navigate the shortage of nirsevimab (Beyfortus), used to immunize infants from RSV.
Read More
A study reveals promising results for even vulnerable individuals, those at high risk of severe COVID-19, who received three doses of mRNA vaccine.
Read More
Patients with both severe asthma and rhinovirus-induced asthma exacerbation may benefit from therapies that block interactions between histamine-releasing factor (HRF) and antibodies called immunoglobulin E (IgE).
Read More
People with severe asthma and rhinovirus-induced asthma exacerbation may benefit from therapies that block interactions between a particular molecule and antibodies, new research finds.
Read More
A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma.
Read MoreThe National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.
Read More
While COVID vaccine-induced neutralizing antibody responses protect against SARS-CoV-2 infection, control of viral replication is mediated by responses that involve T cells and the antibody-binding Fc receptor.
Read More
The FDA revoked the emergency use authorization for the monoclonal antibody Sotrovimab in the Northeastern US due to its ineffectiveness against the Omicron BA.2 subvariant.
Read More
Circulating antiphospholipid antibodies which target a person’s own organs and systems, can also be activated in response to viral infections and may play a role with COVID-19 blood clots.
Read More
The investigational long-acting monoclonal antibody Nirsevimab showed 74.5% efficacy against medically attended lower respiratory tract infections caused by RSV in healthy infants.
Read More
COVID-19 antibody levels were higher in vaccinated mothers and their umbilical cord blood at delivery than in those study participants infected with COVID.
Read More
The FDA authorized Eli Lilly and Co’s bebtelovimab, a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant.
Read More
The FDA has removed two monoclonal antibody therapies from its list of emergency authorized COVID-19 treatments due to their ineffectiveness against the Omicron variant.
Read More
The FDA has issued an emergency use authorization for AstraZeneca’s Evusheld (tixagevimab and cilgavimab) to prevent COVID-19 in certain adults and children.
Read More
A single dose of Regeneron Pharma’s antibody cocktail casirivimab and imdevimab (trade name Regen-Cov) reduced the risk of COVID-19 by 81.6% for up to eight months, according to a Phase 3 trial.
Read More
Researchers testing the prevalence of allergies in babies from farming communities found evidence that mothers pass on protective effects against atopic diseases via their breast milk.
Read More
AstraZeneca has submitted a request to the FDA for an emergency use authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19.
Read More
